Dergiler / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 1

Neutrophil-to-lymphocyte ratio is elevated in recurring nonmuscle invasive bladder cancer

Sayfa
234–239
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our results show that NLR may be used as a predictor of recurrence in patients with NMIBC; however, prospective studies are required to validate these findings.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: Although it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may predict the progression of nonmuscle invasive bladder cancer (NMIBC), its association with the recurrence of NMIBC has been poorly studied.
📊
Temel Bulgular & Veri:Materials and methods: The medical records of 428 consecutive initially diagnosed NMIBC patients who underwent transurethral resection between January 2010 and July 2014 were retrospectively reviewed.
💡
Sonuç & Katkı:Conclusion: Our results show that NLR may be used as a predictor of recurrence in patients with NMIBC; however, prospective studies are required to validate these findings.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2010 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: Although it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may predict the progression of nonmuscle invasive bladder cancer (NMIBC), its association with the recurrence of NMIBC has been poorly studied. The aim of this study is to evaluate the association between NLR and disease recurrence in patients with NMIBC. Materials and methods: The medical records of 428 consecutive initially diagnosed NMIBC patients who underwent transurethral resection between January 2010 and July 2014 were retrospectively reviewed. Patients without a preoperative NLR (n = 6), without a minimum of 6 months of follow-up (n = 56), who were lost to follow-up (n = 38), or who had progressive disease during follow-up (n = 42) were excluded. The demographics, tumor characteristics, and NLRs of patients with and without tumor recurrence were compared. Results: Of 286 patients who met the inclusion criteria, 68 (17.43%) had recurrent disease. Tumor size (P = 0.198), tumor type (P = 0.929), and the presence of carcinoma in situ (P = 0.373) were also similar between groups. Patients with recurrent disease had a higher mean NLR (2.62 ± 0.99 vs. 2.2 ± 0.96, P = 0.002). Conclusion: Our results show that NLR may be used as a predictor of recurrence in patients with NMIBC; however, prospective studies are required to validate these findings.

🔖

Bu Makaleye Atıf Yap

YÜRÜK, E., GÖNÜLTAŞ, S., SAITZ, T. R., ŞEREFOĞLU, E. C., MÜSLÜMANOĞLU, A. Y. (2022). Neutrophil-to-lymphocyte ratio is elevated in recurring nonmuscle invasive bladder cancer. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 1, 234–239. https://ajindex.com/articles/610414

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Vam deer Heijden AG, Sherif A; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014 65: 778-792
  2. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigme JD, Skinner EC, Wolf JS Jr, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. J Urol 2007; 178: 2314-2330
  3. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS; Urologic Diseases in America Project. Recurrence of high-risk bladder cancer: a populationbased analysis. Cancer 2013; 119: 3219-3227. 4. van der Aa MN, Steyerberg EW, Bangma C, van Rhijn BE, Zwarthoff EC, van der Kwast TH. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol 2010; 183: 76-80
  4. Yafi FA, Brimo F, Auger M, Aprikian A, Tanguay S, Kassouf W. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol 2014; 32: 27.e1-6
  5. Schmitz-Dräger BJ, Tirsar LA, Schmitz-Dräger C, Dörsam J, Mellan Z, Bismarck E, Ebert T. Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol 2008; 26: 31-37
  6. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011; 108: 701-705
  7. Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H et al. Considerations on the use of urine markers in the management of patients with high-grade non-muscleinvasive bladder cancer. Urol Oncol 2014; 32: 1069-1077
  8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444
  9. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14
  10. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184
  11. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of n